图片来源:摄图网
近日,港股上市公司德琪医药发布公告称,与翰森制药达成独家合作协议,由翰森制药负责塞利尼索在中国大陆的商业化, 德琪医药将获最高2亿元首付款及最高5.35亿元里程碑付款。
据了解,塞利尼索是德琪医药首个上市商业化产品,从Karyopharm引进,...查看全文
$Karyopharm(KPTI)$ 内部交易: 2020-03-02,Director,Mirza Mansoor Raza ,期权,5000普通股, $8.06
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-016347 Size: 8 KB 网页链接
$Karyopharm(KPTI)$ 8-K Current report, items 1.01, 8.01, and 9.01 Accession Number: 0001193125-20-061643 Act: 34 Size: 455 KB 网页链接
$Karyopharm(KPTI)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001193125-20-061630 Act: 33 Size: 579 KB 网页链接
$Karyopharm(KPTI)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001193125-20-058937 Act: 33 Size: 572 KB 网页链接
$Karyopharm(KPTI)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001193125-20-057801 Act: 34 Size: 215 KB 网页链接
$Karyopharm(KPTI)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001209191-20-014217 Size: 7 KB 网页链接
$Karyopharm(KPTI)$ 8-K Current report, item 5.02 Accession Number: 0001193125-20-054437 Act: 34 Size: 150 KB 网页链接
$Karyopharm(KPTI)$ S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers Accession Number: 0001193125-20-049253 Act: 33 Size: 1 MB 网页链接
$Karyopharm(KPTI)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001193125-20-049115 Act: 34 Size: 13 MB 网页链接